Baidu
map

晚期非小细胞肺癌一线治疗新方法:TG4010+Nivolumab+化疗方案的II期试验

2019-05-28 不详 网络

Transgene是一家生物技术公司,专注于设计和开发用于治疗实体肿瘤的免疫疗法,近日宣布最后一名患者已被纳入II期试验。这项研究将评估TG4010、Opdivo(nivolumab)和化疗联合方案作为晚期非鳞状非小细胞肺癌(NSCLC)一线治疗的有效性和安全性。

Transgene是一家生物技术公司,专注于设计和开发用于治疗实体肿瘤的免疫疗法,近日宣布最后一名患者已被纳入II期试验。这项研究将评估TG4010Opdivonivolumab)和化疗联合方案作为晚期非鳞状非小细胞肺癌NSCLC)一线治疗的有效性和安全性。值得注意的是,这些患者的肿瘤细胞的PD-L1低表达或无表达。

II临床试验正在研究转基因疗法TG4010(一种针对MUC1肿瘤相关抗原的研究性主动免疫疗法),该药物通过克服免疫作用抑制而起抗癌作用。该试验将整体ORR作为主要终点,还将评估该方案的安全性和耐受性以及其他有效性和免疫学参数。


原始出处:

http://www.firstwordpharma.com/node/1643263#axzz5pAuKW7uK

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1903365, encodeId=e615190336596, content=<a href='/topic/show?id=e1b0583884b' target=_blank style='color:#2F92EE;'>#新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58388, encryptionId=e1b0583884b, topicName=新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Thu Aug 15 03:55:00 CST 2019, time=2019-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059806, encodeId=bc2d20598068b, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Sun Jul 21 11:55:00 CST 2019, time=2019-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1933543, encodeId=f1ab1933543d4, content=<a href='/topic/show?id=397a1e335f6' target=_blank style='color:#2F92EE;'>#TG4010#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17335, encryptionId=397a1e335f6, topicName=TG4010)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Thu Mar 12 07:55:00 CST 2020, time=2020-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912141, encodeId=5f9f1912141dd, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sat Dec 14 06:55:00 CST 2019, time=2019-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2083165, encodeId=dc7c2083165fd, content=<a href='/topic/show?id=79e264641cd' target=_blank style='color:#2F92EE;'>#治疗新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64641, encryptionId=79e264641cd, topicName=治疗新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=793a2500200, createdName=12498e5fm12(暂无昵称), createdTime=Sat May 02 19:55:00 CST 2020, time=2020-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007905, encodeId=d470200e90555, content=<a href='/topic/show?id=601512826f6' target=_blank style='color:#2F92EE;'>#NIV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12826, encryptionId=601512826f6, topicName=NIV)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=674961, createdName=tamgche, createdTime=Sat Mar 07 02:55:00 CST 2020, time=2020-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947717, encodeId=3f22194e7172e, content=<a href='/topic/show?id=24ef96066d' target=_blank style='color:#2F92EE;'>#II期试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9606, encryptionId=24ef96066d, topicName=II期试验)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKUdkK5dVTue7YQDvwqM1ugOuEpDZEzvXhoGClFiavehcrNAYDuPbks3MkKLPpyAEicgic80KguxwicYQ/132, createdBy=ec952500165, createdName=ms5187542471278033, createdTime=Sun Apr 26 18:55:00 CST 2020, time=2020-04-26, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1903365, encodeId=e615190336596, content=<a href='/topic/show?id=e1b0583884b' target=_blank style='color:#2F92EE;'>#新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58388, encryptionId=e1b0583884b, topicName=新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Thu Aug 15 03:55:00 CST 2019, time=2019-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059806, encodeId=bc2d20598068b, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Sun Jul 21 11:55:00 CST 2019, time=2019-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1933543, encodeId=f1ab1933543d4, content=<a href='/topic/show?id=397a1e335f6' target=_blank style='color:#2F92EE;'>#TG4010#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17335, encryptionId=397a1e335f6, topicName=TG4010)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Thu Mar 12 07:55:00 CST 2020, time=2020-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912141, encodeId=5f9f1912141dd, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sat Dec 14 06:55:00 CST 2019, time=2019-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2083165, encodeId=dc7c2083165fd, content=<a href='/topic/show?id=79e264641cd' target=_blank style='color:#2F92EE;'>#治疗新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64641, encryptionId=79e264641cd, topicName=治疗新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=793a2500200, createdName=12498e5fm12(暂无昵称), createdTime=Sat May 02 19:55:00 CST 2020, time=2020-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007905, encodeId=d470200e90555, content=<a href='/topic/show?id=601512826f6' target=_blank style='color:#2F92EE;'>#NIV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12826, encryptionId=601512826f6, topicName=NIV)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=674961, createdName=tamgche, createdTime=Sat Mar 07 02:55:00 CST 2020, time=2020-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947717, encodeId=3f22194e7172e, content=<a href='/topic/show?id=24ef96066d' target=_blank style='color:#2F92EE;'>#II期试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9606, encryptionId=24ef96066d, topicName=II期试验)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKUdkK5dVTue7YQDvwqM1ugOuEpDZEzvXhoGClFiavehcrNAYDuPbks3MkKLPpyAEicgic80KguxwicYQ/132, createdBy=ec952500165, createdName=ms5187542471278033, createdTime=Sun Apr 26 18:55:00 CST 2020, time=2020-04-26, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1903365, encodeId=e615190336596, content=<a href='/topic/show?id=e1b0583884b' target=_blank style='color:#2F92EE;'>#新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58388, encryptionId=e1b0583884b, topicName=新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Thu Aug 15 03:55:00 CST 2019, time=2019-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059806, encodeId=bc2d20598068b, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Sun Jul 21 11:55:00 CST 2019, time=2019-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1933543, encodeId=f1ab1933543d4, content=<a href='/topic/show?id=397a1e335f6' target=_blank style='color:#2F92EE;'>#TG4010#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17335, encryptionId=397a1e335f6, topicName=TG4010)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Thu Mar 12 07:55:00 CST 2020, time=2020-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912141, encodeId=5f9f1912141dd, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sat Dec 14 06:55:00 CST 2019, time=2019-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2083165, encodeId=dc7c2083165fd, content=<a href='/topic/show?id=79e264641cd' target=_blank style='color:#2F92EE;'>#治疗新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64641, encryptionId=79e264641cd, topicName=治疗新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=793a2500200, createdName=12498e5fm12(暂无昵称), createdTime=Sat May 02 19:55:00 CST 2020, time=2020-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007905, encodeId=d470200e90555, content=<a href='/topic/show?id=601512826f6' target=_blank style='color:#2F92EE;'>#NIV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12826, encryptionId=601512826f6, topicName=NIV)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=674961, createdName=tamgche, createdTime=Sat Mar 07 02:55:00 CST 2020, time=2020-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947717, encodeId=3f22194e7172e, content=<a href='/topic/show?id=24ef96066d' target=_blank style='color:#2F92EE;'>#II期试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9606, encryptionId=24ef96066d, topicName=II期试验)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKUdkK5dVTue7YQDvwqM1ugOuEpDZEzvXhoGClFiavehcrNAYDuPbks3MkKLPpyAEicgic80KguxwicYQ/132, createdBy=ec952500165, createdName=ms5187542471278033, createdTime=Sun Apr 26 18:55:00 CST 2020, time=2020-04-26, status=1, ipAttribution=)]
    2020-03-12 xlxchina
  4. [GetPortalCommentsPageByObjectIdResponse(id=1903365, encodeId=e615190336596, content=<a href='/topic/show?id=e1b0583884b' target=_blank style='color:#2F92EE;'>#新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58388, encryptionId=e1b0583884b, topicName=新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Thu Aug 15 03:55:00 CST 2019, time=2019-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059806, encodeId=bc2d20598068b, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Sun Jul 21 11:55:00 CST 2019, time=2019-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1933543, encodeId=f1ab1933543d4, content=<a href='/topic/show?id=397a1e335f6' target=_blank style='color:#2F92EE;'>#TG4010#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17335, encryptionId=397a1e335f6, topicName=TG4010)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Thu Mar 12 07:55:00 CST 2020, time=2020-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912141, encodeId=5f9f1912141dd, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sat Dec 14 06:55:00 CST 2019, time=2019-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2083165, encodeId=dc7c2083165fd, content=<a href='/topic/show?id=79e264641cd' target=_blank style='color:#2F92EE;'>#治疗新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64641, encryptionId=79e264641cd, topicName=治疗新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=793a2500200, createdName=12498e5fm12(暂无昵称), createdTime=Sat May 02 19:55:00 CST 2020, time=2020-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007905, encodeId=d470200e90555, content=<a href='/topic/show?id=601512826f6' target=_blank style='color:#2F92EE;'>#NIV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12826, encryptionId=601512826f6, topicName=NIV)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=674961, createdName=tamgche, createdTime=Sat Mar 07 02:55:00 CST 2020, time=2020-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947717, encodeId=3f22194e7172e, content=<a href='/topic/show?id=24ef96066d' target=_blank style='color:#2F92EE;'>#II期试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9606, encryptionId=24ef96066d, topicName=II期试验)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKUdkK5dVTue7YQDvwqM1ugOuEpDZEzvXhoGClFiavehcrNAYDuPbks3MkKLPpyAEicgic80KguxwicYQ/132, createdBy=ec952500165, createdName=ms5187542471278033, createdTime=Sun Apr 26 18:55:00 CST 2020, time=2020-04-26, status=1, ipAttribution=)]
    2019-12-14 snf701207
  5. [GetPortalCommentsPageByObjectIdResponse(id=1903365, encodeId=e615190336596, content=<a href='/topic/show?id=e1b0583884b' target=_blank style='color:#2F92EE;'>#新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58388, encryptionId=e1b0583884b, topicName=新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Thu Aug 15 03:55:00 CST 2019, time=2019-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059806, encodeId=bc2d20598068b, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Sun Jul 21 11:55:00 CST 2019, time=2019-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1933543, encodeId=f1ab1933543d4, content=<a href='/topic/show?id=397a1e335f6' target=_blank style='color:#2F92EE;'>#TG4010#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17335, encryptionId=397a1e335f6, topicName=TG4010)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Thu Mar 12 07:55:00 CST 2020, time=2020-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912141, encodeId=5f9f1912141dd, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sat Dec 14 06:55:00 CST 2019, time=2019-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2083165, encodeId=dc7c2083165fd, content=<a href='/topic/show?id=79e264641cd' target=_blank style='color:#2F92EE;'>#治疗新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64641, encryptionId=79e264641cd, topicName=治疗新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=793a2500200, createdName=12498e5fm12(暂无昵称), createdTime=Sat May 02 19:55:00 CST 2020, time=2020-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007905, encodeId=d470200e90555, content=<a href='/topic/show?id=601512826f6' target=_blank style='color:#2F92EE;'>#NIV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12826, encryptionId=601512826f6, topicName=NIV)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=674961, createdName=tamgche, createdTime=Sat Mar 07 02:55:00 CST 2020, time=2020-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947717, encodeId=3f22194e7172e, content=<a href='/topic/show?id=24ef96066d' target=_blank style='color:#2F92EE;'>#II期试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9606, encryptionId=24ef96066d, topicName=II期试验)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKUdkK5dVTue7YQDvwqM1ugOuEpDZEzvXhoGClFiavehcrNAYDuPbks3MkKLPpyAEicgic80KguxwicYQ/132, createdBy=ec952500165, createdName=ms5187542471278033, createdTime=Sun Apr 26 18:55:00 CST 2020, time=2020-04-26, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1903365, encodeId=e615190336596, content=<a href='/topic/show?id=e1b0583884b' target=_blank style='color:#2F92EE;'>#新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58388, encryptionId=e1b0583884b, topicName=新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Thu Aug 15 03:55:00 CST 2019, time=2019-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059806, encodeId=bc2d20598068b, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Sun Jul 21 11:55:00 CST 2019, time=2019-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1933543, encodeId=f1ab1933543d4, content=<a href='/topic/show?id=397a1e335f6' target=_blank style='color:#2F92EE;'>#TG4010#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17335, encryptionId=397a1e335f6, topicName=TG4010)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Thu Mar 12 07:55:00 CST 2020, time=2020-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912141, encodeId=5f9f1912141dd, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sat Dec 14 06:55:00 CST 2019, time=2019-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2083165, encodeId=dc7c2083165fd, content=<a href='/topic/show?id=79e264641cd' target=_blank style='color:#2F92EE;'>#治疗新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64641, encryptionId=79e264641cd, topicName=治疗新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=793a2500200, createdName=12498e5fm12(暂无昵称), createdTime=Sat May 02 19:55:00 CST 2020, time=2020-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007905, encodeId=d470200e90555, content=<a href='/topic/show?id=601512826f6' target=_blank style='color:#2F92EE;'>#NIV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12826, encryptionId=601512826f6, topicName=NIV)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=674961, createdName=tamgche, createdTime=Sat Mar 07 02:55:00 CST 2020, time=2020-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947717, encodeId=3f22194e7172e, content=<a href='/topic/show?id=24ef96066d' target=_blank style='color:#2F92EE;'>#II期试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9606, encryptionId=24ef96066d, topicName=II期试验)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKUdkK5dVTue7YQDvwqM1ugOuEpDZEzvXhoGClFiavehcrNAYDuPbks3MkKLPpyAEicgic80KguxwicYQ/132, createdBy=ec952500165, createdName=ms5187542471278033, createdTime=Sun Apr 26 18:55:00 CST 2020, time=2020-04-26, status=1, ipAttribution=)]
    2020-03-07 tamgche
  7. [GetPortalCommentsPageByObjectIdResponse(id=1903365, encodeId=e615190336596, content=<a href='/topic/show?id=e1b0583884b' target=_blank style='color:#2F92EE;'>#新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58388, encryptionId=e1b0583884b, topicName=新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Thu Aug 15 03:55:00 CST 2019, time=2019-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059806, encodeId=bc2d20598068b, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Sun Jul 21 11:55:00 CST 2019, time=2019-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1933543, encodeId=f1ab1933543d4, content=<a href='/topic/show?id=397a1e335f6' target=_blank style='color:#2F92EE;'>#TG4010#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17335, encryptionId=397a1e335f6, topicName=TG4010)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Thu Mar 12 07:55:00 CST 2020, time=2020-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912141, encodeId=5f9f1912141dd, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sat Dec 14 06:55:00 CST 2019, time=2019-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2083165, encodeId=dc7c2083165fd, content=<a href='/topic/show?id=79e264641cd' target=_blank style='color:#2F92EE;'>#治疗新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64641, encryptionId=79e264641cd, topicName=治疗新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=793a2500200, createdName=12498e5fm12(暂无昵称), createdTime=Sat May 02 19:55:00 CST 2020, time=2020-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007905, encodeId=d470200e90555, content=<a href='/topic/show?id=601512826f6' target=_blank style='color:#2F92EE;'>#NIV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12826, encryptionId=601512826f6, topicName=NIV)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=674961, createdName=tamgche, createdTime=Sat Mar 07 02:55:00 CST 2020, time=2020-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947717, encodeId=3f22194e7172e, content=<a href='/topic/show?id=24ef96066d' target=_blank style='color:#2F92EE;'>#II期试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9606, encryptionId=24ef96066d, topicName=II期试验)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKUdkK5dVTue7YQDvwqM1ugOuEpDZEzvXhoGClFiavehcrNAYDuPbks3MkKLPpyAEicgic80KguxwicYQ/132, createdBy=ec952500165, createdName=ms5187542471278033, createdTime=Sun Apr 26 18:55:00 CST 2020, time=2020-04-26, status=1, ipAttribution=)]
Baidu
map
Baidu
map
Baidu
map